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Abstract
MicroRNAs’ dysregulation and profiling have been demonstrated to be clinically relevant in urothelial carcinoma (UC). Urine
cytology is commonly used as the mainstay non-invasive test for secondary prevention and follow-up of UC patients.
Ancillary tools are needed to support cytopathologists in the diagnosis of low-grade UC. The feasibility and reliability of
microRNAs profiling by qRT-PCR analysis (miR-145 and miR-205) in archival routine urine cytology smears (affected by
fixation/staining [Papanicolau] and room temperature storage) was tested in a series of 15 non-neoplastic and 10 UC urine
specimens. Only samples with .5,000 urothelial cells and with ,50% of inflammatory cells/red blood cells clusters were
considered. Overall, a satisfactory amount of total RNA was obtained from all the considered samples (mean 1.2761.43 mg,
range 0.06–4.60 mg). Twenty nanograms of total RNA have been calculated to be the minimal total RNA concentration for
reliable and reproducible miRNAs expression profiling analysis of archival cytological smears (slope = -3.4084; R-
squared = 0.99; efficiency = 1.94). miR-145 and miR-205 were significantly downregulated in UC samples in comparison to
non-tumor controls. These findings demonstrate that urine archival cytology smears are suitable for obtaining high-quality
RNA to be used in microRNAs expression profiling. Further studies should investigate if miRNAs profiling can be successfully
translated into clinical practice as diagnostic or prognostic markers.
Citation: Simonato F, Ventura L, Sartori N, Cappellesso R, Fassan M, et al. (2013) Detection of MicroRNAs in Archival Cytology Urine Smears. PLoS ONE 8(2):
e57490. doi:10.1371/journal.pone.0057490
Editor: Aldo Scarpa, University of Verona, Italy
Received November 27, 2012; Accepted January 22, 2013; Published February 28, 2013
Copyright:  2013 Simonato et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant from the Veneto Region (Ricerca Finalizzata 2006), by a grant from the University of Padova (Progetti di Ricerca di
Ateneo 2011) and by the Cariparo Foundation Excellence-grant 2011/2012. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ambrogio.fassina@unipd.it
Introduction
Bladder cancer represents the fourth male most common cancer
in the western world and urothelial cell carcinoma (UC; previously
designated as transitional carcinoma [TCC]) accounts for
approximately 95% of bladder malignancies and is the most
common tumor detected by urine cytology [1]. Two distinct
phenotypic and molecular pathways have been demonstrated in
UC: i) the superficial papillary carcinoma, accounting for more
than 80% of bladder tumors, with tendency to recur locally
(approximately 70%), with rare invasion and metastasis; ii) and the
invasive non-papillary bladder tumor, without known papillary
precursor, which is commonly associated with carcinoma in situ
(CIS) with unfavourable prognosis [2,3].
Urine cytology is widely and routinely employed as: i) the
preliminary analysis in the evaluation of patients presenting with
haematuria or painful urination suggestive for urinary system
pathology [4]; ii) screening test for the early detection of bladder
cancer in selected populations exposed to known bladder
carcinogens; and iii) the mainstay in the follow-up of patients
with a history of malignancy involving the urinary tract [4,5].
While the reported sensitivity and specificity of urine cytology in
the diagnosis of high-grade UC exceed 90% [6], its sensitivity and
specificity drastically drop-down for low-grade cases [7].
To date, several biomarkers, such as bladder tumor antigen
(BTA) [8], nuclear mitotic apparatus protein 22 (NMP22) [9],
ImmunoCytTM, and UroVysionTM [10], have been proposed to
ancillary support the cytological diagnosis (in particular in the
presence of low-grade lesions); however, none of these provided
substantial help to the diagnostic process [3].
MicroRNAs (miRNAs) are a class of short (,20 nucleotides),
regulatory, non-coding RNA, involved in several cellular processes
in both development and pathology [11–13]. Unlike most RNAs,
miRNAs are long-lasting in vivo and very stable in vitro, which is
critical in the clinical setting [14]. Indeed, miRNAs have been
detected in whatever human specimen (tissue, blood, plasma,
serum, sputum, feces, CSF, and urine) yielding their recognition
relatively simple and often non-invasive [15–18]. Moreover,
miRNA profiling methods have been showed to be standardizable
and of clinical impact in human cancers [19,20]. Altogether, such
characteristics pinpointed miRNAs as suitable biomarkers to be
detected even in scant degraded cytology samples affected by
fixation/staining and room temperature storage such as routine
diagnostics urine smears.
Since the pioneering report by Gottardo et al. [12], describing
up-regulation of a set of miRNAs in 27 UC vs 2 normal bladder
mucosa samples, to date, several large profiling studies in tumor
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resections and cell cultures have been described [21–26]. Among
the others, the down-regulation of miR-145 has been demonstrat-
ed to reliable differentiate low-grade UC from normal urothelium
[22,25]. Instead, miR-205 has been reported to be early down-
regulated during UC carcinogenesis [23,24], but over-expressed in
progressed tumors [12,26].
In a series of non-neoplastic and UC urine archival cytological
specimens, we tested the feasibility and reliability of profiling
analysis of two down-regulated UC miRNA biomarkers (miR-145
and miR-205). Our data provide further evidence on miRNAs as




Written informed consent was obtained from all participants
involved in the study, which was approved (number approval N
0002539) by the institutional review board of the University
Hospital of Padua (Azienda Ospedaliera di Padova – Università
degli Studi di Padova).
Patients & Specimens
From the archives of the Surgical Pathology and Cytopathology
Unit at Padua University (Cytopathology Unit) was retrieved
a total of 10 consecutive low-grade UC and 15 consecutive non-
neoplastic cytology samples reported in 2009 (.36 months old).
Original routine cytological slides (Cytofix-fixed [Bio-Fix 05-x200,
Bio-Optica, Milano, Italy] and Papanicolaou-stained) were jointly
re-assessed by two pathologists (RC and MF) accordingly to the
current WHO criteria [2,27]; in cases where their opinions
differed, a third expert cytologist (AF) was involved. All low-grade
UC cytological diagnoses were also histologically confirmed in
bladder biopsies sampled during the following cystoscopy [2].
The presence of .5,000 well-preserved and well-visualized
urothelial cells (as observed in 10 fields at 4x magnification) were
appointed as minimum accepted cellularity. In neoplastic speci-
mens, only slides with a proportion of tumor cells .25% were
selected. Slides with .50% of urothelial cells obscured by either
white or red blood cells were excluded (Figure 1).
Overall, the male:female ratio was 8:2 and mean age was
81.767.7 years (median= 84; range = 67–92) for UC patients,
while male:female ratio was 8:7 and mean age was 64.5611.2
years (median 66; range 44–81) for the non-neoplastic patients.
Cell Cultures
As reference for the qRT-PCR analyses, Capan-1 and BxPc3
cell lines were purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA) and maintained as
recommended. Cell proliferation and counting was determined by
monitoring each cell line with the xCELLigence system (Roche,
Mannheim, Germany). xCELLigence cell index impedance
measurements were performed according to the instructions of
the supplier. Cells (56103 cells/well) were seeded in 150 ml of the
complete medium in a 16-well microtiter plate specifically
designed to measure cellular impedance (E-plate; Roche) and
placed into the xCELLigence system for data collection after
a 30 min incubation at room temperature. The xCELLigence
software was set to collect impendence data (reported as cell index)
at least once every 15 min for 4 days. Overall, 106 cells at
exponentially growth phase was yielded from each cell line for
total RNA extraction, after routine spotting, fixation, and staining
(as for the urine samples).
RNA Extraction
Coverslips were removed by immersion in xylene for 72 hours
and the slides were rinsed three times in 95% ethanol. Cells on the
slides were scraped in 1.5 ml tubes by using sterile razors and
suspended in 500 ml of TRIzol reagent (Invitrogen, Carlsbad, CA)
for total RNA isolation according to the manufacturer’s instruc-
tions [28]. Amount and purity of RNA was assessed by UV
spectrometry (Nanodrop ND1000, Thermo Scientific, Wilming-
ton, DE).
Quantitative Reverse-transcription-PCR
RNA dilutions were retro-transcribed by using the VILO cDNA
Synthesis kit (Invitrogen). To detect and quantify mature hsa-miR-
145 (miR-145; primer sequence: 59- CAG TTT TCC CAG GAA
TCC CT-39) and hsa-miR-205 (miR-205; primer sequence: 59-
CTT CAT TCC ACC GGA GTC TG -39), the NCodeTM
miRNA qRT–PCR method (Invitrogen) was used on the Light-
Cycler 480 Real-Time PCR System (Roche Diagnostic, Man-
nheim, Germany), as reported elsewhere [19,28]. The results were
normalized with the small nuclear RNA U6B (RNU6B; primer
sequence: 59- ACG CAA ATT CGT GAA GCG TT -39;
Invitrogen). All the reactions were run in triplicate, including no-
template controls. A total of seven serial RNA dilutions for each
non-neoplastic urine sample (50 ng, 40 ng, 30 ng, 20 ng, 10 ng,
1 ng, and 0.1 ng) and a total of eight RNA dilutions for cell lines
(50 ng, 40 ng, 30 ng, 20 ng, 10 ng, 5 ng, 1 ng, 0.1 ng) were tested
for miR-205 and RNU6B in order to define the minimal adequate
RNA quantity to use for miRNAs qRT-PCR analysis. To support
the data, differences in miR-145 and miR-205 expression were
tested in non-neoplastic and UC urine cytological specimens.
Statistical Analysis
Statistical analyses for testing the qRT-PCR efficiency were
based on the results of experiments on routine cytology samples
and two cell lines. The experiments were performed separately for
RNU6B, miR-145and miR-205. The threshold cycle (Ct) was
plotted against the log10 amount of cDNA input (ldose). The
focused parameter was the slope of the relationship between ldose
and Ct, since it was used to estimate the efficiency e of the qRT-
PCR, according to the equation e=–10/slope. The ideal slope is
23.32, which corresponds to an amplification efficiency of 100%
(e=2). A slope comprised in the range of 23.6 to 23.1 is
considered acceptable for qRT-PCR results [29]. For the two cell
lines we investigated the relationship between Ct and ldose
through linear regression models. For the urine samples, linear
mixed effects (LME) regression models including a random effect
for the subject were used. This class of models is needed to deal
with intra-individual variability. The best doses were selected in
terms of the estimated slopes. A likelihood ratio test R2 was
computed for LME to summarize how well the model explains the
data [30]. The significance level for all statistical analyses was set
at a=0.05. Differential expression between non-neoplastic and
UC samples were tested for both miR-205 and miR-145 using the
Welsh two-sided t-test. All statistical analyses were performed
using the R software (R Development Core Team, version 2.9; R
Foundation for Statistical Computing, Vienna, Austria; www.R-
project.org).
Results
Total RNA Obtained from Archival Urine Cytology Smears
As showed in Table 1, total RNA was successfully extracted
from all the 25 urine cytological specimens and the mean RNA
yield per sample was 1.2761.43 mg (median= 0.88; range= 0.06–
MiRNA Detection in Urine Archival Cytology Samples
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4.60), with a OD260/280 ratio of 1.9660.34 (median = 1.94;
range = 1.7–2.2). Only one sample presented a lower RNA purity
with a OD260/280 ratio of 2.80 (case #9), but was retained in the
analysis. As expected, the purity and quantity of extracted RNA
were higher in the two cell lines (RNA obtained from 106 cells,
routinely fixed/stained and room temperature stored): CAPAN-1
Figure 1. Selection of the cytology specimens. Only cases with .5,000 well-preserved and well-visualized urothelial cells (as observed in 10
fields at 4x magnification) were selected. Cases largely constituted by red blood cells or inflammatory cells were excluded.
doi:10.1371/journal.pone.0057490.g001
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RNA yield 10.8 mg and OD260/280 ratio of 1.85; BxPC3 RNA
yield 15.2 mg and OD260/280 ratio of 1.92.
To estimate the efficiency e of the qRT-PCR obtained by
cytology smear and to test the relationship between Ct and ldose,
a covariance analysis (ANCOVA) model was applied to the two
cell lines (Capan-1 and BxPC3). The best cut-off for RNA amount
to obtain a proper qRT-PCR analysis was selected in terms of the
estimated slope (Table 2). All the diagnostics supported the
estimated ANCOVA models. For RNA U6B, when considering all
the tested dilutions (i.e., 50 ng, 40 ng, 30 ng, 20 ng, 10 ng, 5 ng,
1 ng, 0.1 ng), the ANCOVA analysis (R2= 0.99) revealed that the
slope of the relationship between ldose and Ct was the same in the
two cell lines (p = 0.55) and it was equal to 23.73 (60.07,
p,0.0001), with efficiency e=1.70. The Ct measurements were
systematically lower in Capan-1 compared with BxPC3 (-
2.6860.12, p,0.0001). When considering amount of total RNA
$1 ng, the ANCOVA analysis (R2= 0.99) showed that the slope
of the relationship between ldose and Ct was equal to 23.561
(60.11, p,.0001), with efficiency e=1.81. The estimated models
are Ct = 27.65–3.55*ldose for BxPc3 and Ct= 24.97–3.55*ldose
for Capan-1 (Figure 2A). For miR-205, when considering all the
dilutions, ANCOVA analysis (R2= 0.98) revealed that the slope of
the relationship between ldose and Ct was the same in the two cell
lines and was equal to 24.00 (60.12, p,.0001), with efficiency
e=1.50. When considering amount of total RNA $5 ng, the
ANCOVA model (R2=0.91) showed that the slope of the
relationship between ldose and Ct was 23.649 (60.39, p,.000),
with efficiency e=1.75. The estimated model was Ct = 29.09–
3.64*ldose both for BxPC3 and Capan-1 (Figure 2B).
RNA Extracted from Cytology Smear is Suitable for qRT-
PCR Analysis
To validate these results in long-stored urine archival smears,
a total of 15 non-neoplastic urine smears were investigated, by
applying a LME model including a random effect for the subject.
The minimal RNA amount to perform an adequate qRT-PCR
analysis was selected in terms of the fixed effect slope (Table 2). All
the diagnostics on the residuals supported the estimated LME
models. For RNA U6B, when considering all the tested dilutions,
LME analysis (R2= 0.92) revealed that the fixed effect slope of the
relationship between ldose and Ct was equal to 22.43 (60.29,
p,0.000), with efficiency e=3.11. When considering RNA
amount $10 ng, the LME analysis (R2= 0.99) showed that the
fixed effect slope of the relationship between ldose and Ct was
equal to 22.966 (60.33, p,0.000), with efficiency e=2.37. The
estimated model was Ct = 33.23–2.966*ldose. For miR-205, when
considering all dilutions, the LME analysis (R2= 0.54) revealed
that the fixed effect slope of the relationship between ldose and Ct
was 21.73 (60.13, p,0.000), with efficiency e=4.78. When
Table 1. Cytological and molecular features of the 25 cytology samples.
Sample Type RNA yield (mg) A260/A280 ratio Cellularity Cell types
Cancer Inflammatory
1 NT 1.28 1.74 H – 5%
2 NT 1.52 1.80 H – 10%
3 NT 0.88 1.01 L – –
4 NT 2.60 1.96 H – –
5 NT 2.92 2.30 H – 5%
6 NT 4.60 2.24 H – 30%
7 NT 4.44 2.25 H – 20%
8 NT 0.08 1.90 L – 10%
9 NT 0.29 2.80 L – –
10 NT 0.06 1.92 L – –
11 NT 2.21 2.01 H – –
12 NT 1.04 1.71 H – 15%
13 NT 1.32 1.94 H – 10%
14 NT 1.15 1.71 H – 5%
15 NT 0.94 1.74 L – 5%
16 T 0.17 2.22 L 40% 10%
17 T 0.11 2.25 L 30% 20%
18 T 0.25 2.25 L 50% 5%
19 T 0.16 2.00 L 35% 15%
20 T 0.13 2.24 L 70% 10%
21 T 0.25 2.01 L 60% 10%
22 T 4.20 1.88 H 50% 5%
23 T 0.16 1.68 L 30% 15%
24 T 0.48 1.66 L 40% 20%
25 T 0.62 1.71 H 50% 10%
Note: NT= non-tumor; T = tumor; H =.10,000 cells; L =.5,000 and ,10,000 cells.
doi:10.1371/journal.pone.0057490.t001
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considering RNA amount $20 ng, the LME analysis (R2= 0.99)
showed that the fixed effect slope of the relationship between ldose
and Ct was23.41 (60.36, p,.000), with efficiency e=1.94. These
data pinpoint 20 ng of total RNA as the minimum cut-off to use in
miRNA expression profiling in archival urine cytology specimens.
Archival Urine Cytology Smears for miRNA Expression
Profiling Studies
Both miR-145 and miR-205 were significantly down-regulated
in UC specimens in comparison with non-neoplastic smears
(27.25 and 23.46, respectively; p,0.05) (Figure 3). These
Figure 2. Identification of the minimal RNA quantity to obtain an adequate qRT-PCR reaction from cytology specimens. (A) The
relationship between Ct and ldose for the two cell lines (BxPc3 and Capan-1) was analyzed as covariance (ANCOVA) model and the minimal RNA
quantity was identified in terms of the estimated slope. For RNU6B, the ANCOVA analysis (R2 = 0.99) revealed that the slope of the relationship
between ldose and Ct is the same in the two cells lines (p = 0.55) and it is equal to 23.73 (60.07, p,0.0001), with efficiency e= 1.70. The estimated
models are Ct = 27.65–3.55*ldose for BxPc3 and Ct = 24.97–3.55*ldose for Capan-1. (B) For miR-205 ANCOVA analysis (R2 = 0.98) revealed that the
slope of the relationship between ldose and Ct is the same in the two cell lines and is equal to 24.00 (60.12, p,0.000), with efficiency e= 1.50. The
estimated model is Ct = 29.09–3.64*ldose both for BxPc3 and Capan-1. (C) To estimate the relationship between Ct and ldose on the 15 non-
neoplastic patients, we used linear mixed effect models including a random effect for the subject. (D) The minimal RNA quantity was selected in
terms of the fixed effect slope. For miR-205, when considering all the dilutions, the LME analysis (R2 = 0.92) revealed that the fixed effect slope of the
relationship between ldose and Ct is 21.73 (60.13, p,0.000), with efficiency e= 4.78.
doi:10.1371/journal.pone.0057490.g002
Table 2. RNA amount cut-off values for qRT-PCR analysis using archival cytology smears.
Material Gene RNA amount cut-off Slope R-squared Efficiency
Cell lines RNA U6B 1 ng 23.561 0.99 1.81
miR-205 5 ng 23.649 0.91 1.75
Non-tumor urine smears RNA U6B 10 ng 22.966 0.99 2.37
miR-205 20 ng 23.408 0.99 1.94
doi:10.1371/journal.pone.0057490.t002
MiRNA Detection in Urine Archival Cytology Samples
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findings validate miRNA expression profiling by using total RNA
extracted from archival urine specimens.
Discussion
Formalin fixed and paraffin embedded (FFPE) tissues contain
virtually all the information that confirm the central position of
clinical pathology in diagnosis, prognosis, therapy recommenda-
tion, and disease mechanism insight. Well along in this pathway,
cytopathology runs a parallel and successful track: many patients
cannot undergo an open biopsy and cytological smears are the
only tissue available for diagnosis. Moreover, disease and
treatment modifications can be monitored via repeated sampling,
as e.g. for urine in UC or effusions for carcinomas metastatic to
serosal cavities.
UC involves the urinary tract and represents the fourth most
common cancer in men in the western world. UC is characterized
by frequent recurrences comprised between 50% and 70%, and
10–15% of patients develops muscle invasion over a 5-yr period,
requiring in many cases a longtime surveillance [1].
The gold standard for primary detection and follow-up of UC
consists of cystoscopy and cytology [31]. Cystoscopy identifies
most of papillary and solid lesions, but it is invasive and
uncomfortable for patients and causes a urinary tract infection
in around 10% of the patients [32]. Urine cytology has a specificity
of 93% to detect high-grade tumors with a reasonable sensitivity,
but such sensitivity drops down to 4–31% for low-grade UC cases
[7]. Therefore there is a clear need for more accurate urinary UC
biomarkers.
As aforementioned, various molecular urinary biomarkers have
been developed to improve UC detection; however, none of these
showed a satisfying sensitivity or specificity for replacing cystos-
copy, even coupled with cytology. A relatively new class of
biomarkers (i.e. miRNAs) has been proposed for diagnostics,
treatment monitoring and therapeutic approach in oncology.
In this paper, we first defined the minimal total RNA
concentration for a reliable and reproducible miRNAs expression
profiling analysis. Then, in order to demonstrate that archival
cytology specimens are still informative for diagnostic purpose, we
examined total RNA from 15 non-neoplastic and 10 UC cytology
samples obtaining from each a good quantity (ranged between
0.06–4.44 mg) and good purity (OD260/280 nm ratio between 1.7
and 2.3) of total RNA.
To further support the data, we analyzed the expression of miR-
145 and miR-205, which have been recently associated to UC
[12,21–25]. Indeed, it has been reported that miR-145 expression
is significantly reduced in resected specimens of low-grade, in situ,
and muscle invasive UC [22,25], while miR-205 is consistently
down-regulated in progressing UC since its direct involvement in
early bladder carcinogenesis [23,24].
Our preliminary results noticeably reproduced in the archival
urine specimens the findings obtained in resected samples
corroborating the hypothesis that miRNAs expression profiling
analysis is feasible and reliable even in such scant and degraded
material.
Numerous, recent studies have explored circulating cell-free
(mainly exosome-based) miRNAs and provided evidence that
miRNAs exist in a stable form in various body fluids, such as
blood, urine, saliva, and peritoneal fluid [15–18,33]. Moreover,
such papers have shown that miRNA signatures in body fluids are
not affected by age and sex differences ruling out a possible bias in
this study introduced by random selection of consecutive tumors
and control urine cytology samples instead of specimens from
matched populations [15,16,34]. Of interest, a recent study
identified members of miR-200 family, miR-155, miR-192 and
miR-205, as reliable UC biomarkers in fresh urine for long-term
surveillance of UC patients [34]. It has to be underlined that,
contrarily to fresh urine, cytology urine samples are always steadily
available as they are stored in pathology and cytopathology
archives for many years. Other intriguing miRNAs to be tested in
large series of UC cases are miR-129, since its over-expression has
been implicated in apoptosis avoidance by direct targeting of
SOX4 and GALNT1 [22], and miR-200 family, since its down-
regulation has been involved in the complex process known as
epithelial-mesenchymal transition (EMT) [23,26,28].
Of interest, the method here presented, after a preliminary
assessment of specimen cellularity and tumor cell ratio, could be
virtually applied to whatever sample stored in cytopathology
archives, from fine-needle aspirates to effusions and bronchoal-
veolar lavages. Further studies should evaluate this fascinating
possibility.
Figure 3. Total RNA extracted from archival urine cytology smears is suitable for miRNA expression profiling. Box plots show
differences in miRNAs expression between non-tumor (NT) and low grade urothelial carcinoma samples (T). *p,0.05.
doi:10.1371/journal.pone.0057490.g003
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Conclusions
Our preliminary data opens a broad field of immediately
available and low cost diagnostic samples to shed new light on
urinary tract cancer. Larger studies should assess the wide
spectrum of significant miRNAs involved in bladder cancer to
be applied in clinical practice as diagnostic, prognostic, and
predictive markers.
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